Home » Qualitest, Endo Labeling Mixup Behind Generic Pain Drug Recall

Qualitest, Endo Labeling Mixup Behind Generic Pain Drug Recall

July 26, 2011

Generic-drug maker Qualitest Pharmaceuticals and its parent company, Endo Pharmaceuticals, separately announced recalls of common pain drugs — marking the second labeling-related recall this year for Qualitest.
Generic Line

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Qualitest, Endo Labeling Mixup Behind Generic Pain Drug Recall

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

Vetex Medical’s Thrombectomy Catheter Cleared by FDA

Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements